DeCure for Arrhythmogenic right ventricular cardiomyopathy
DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for arrhythmogenic right ventricular cardiomyopathy — screening already-approved drugs against its 32-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleArrhythmogenic right ventricular cardiomyopathy maps to a 32-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for arrhythmogenic right ventricular cardiomyopathy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
transforming growth factor beta 3 (TGFB3) — TGFB3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet diodrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1TGJ · 2.0 Å · ligand 1,4-DIETHYLENE DIOXIDE (DIO). Experimental structure, not a prediction.
What the evidence adds up to
Arrhythmogenic right ventricular cardiomyopathy (ARVC) was first described 35 years before 2019, and desmosomal gene mutations were established as a major cause more than 20 years before that date. The disease is pathologically characterised by progressive right ventricular myocardial atrophy and fibrofatty replacement, and clinically by ventricular arrhythmias with left bundle branch block morphology. Symptoms poorly reflect disease severity, and the disease commonly first manifests as sudden death among the young. Inflammatory and apoptotic theories do not explain all cases, and various non-mutually exclusive pathogenetic mechanisms appear to underlie ARVC.
Consensus diagnostic criteria from the Task Force proved sensitive but not entirely specific for the disease. By 2019, clinical and genetic data from families and recognition of a broader spectrum of structural disorders affecting both ventricles raised many questions about pathogenesis, disease terminology and clinical management. Diagnosis remains problematic and is frequently made only by autopsy. Early diagnosis to prevent sudden cardiac death is considered essential.
Two case reports from 2015 describe patients with ARVC who underwent orthotopic heart transplant. The authors state that heart transplant can be a real therapeutic option for these patients and offered the possibility to confirm the diagnosis and better understand pathological and histological features. Criteria for heart transplant had still not been well defined at that time.
What is still missing is a clear, specific diagnostic test that does not rely on autopsy or explanted heart examination, and well-defined criteria for when to proceed to heart transplant. The broader terminology and clinical management of arrhythmogenic cardiomyopathies remain unsettled, and the pathogenesis is not fully explained by any single mechanism. No drug treatment is mentioned in these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Heart · 1994 · 1652 citations · open access
Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology.
AbstractDiagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology.
European Journal of Heart Failure · 2019 · 119 citations · open access
Definition and Treatment of Arrhythmogenic Cardiomyopathy: An Updated Expert Panel Report
AbstractIt is 35 years since the first description of arrhythmogenic right ventricular cardiomyopathy (ARVC) and more than 20 years since the first reports establishing desmosomal gene mutations as a major cause of the disease. Early advances in the understanding of the clinical, pathological and genetic architecture of ARVC resulted in consensus diagnostic criteria, which proved to be sensitive but not entirely specific for the disease. In more recent years, clinical and genetic data from families and the recognition of a much broader spectrum of structural disorders affecting both ventricles and associated with a propensity to ventricular arrhythmia have raised many questions about pathogenesis, disease terminology and clinical management. In this paper, we present the conclusions of an expert round table that aimed to summarise the current state of the art in arrhythmogenic cardiomyopathies and to define future research priorities.
Traditional vs. genetic pathogenesis of arrhythmogenic right ventricular cardiomyopathy
AbstractArrhythmogenic right ventricular cardiomyopathy (ARVC), a predominantly familial and autosomal dominant inherited heart muscle disorder, is pathologically characterized by progressive right ventricular myocardial atrophy and fibrofatty replacement and clinically by ventricular arrhythmias with left bundle branch block morphology. Symptoms poorly reflect disease severity, with disease commonly first manifesting as sudden death among the young. The inflammatory and apoptotic theories first put forth to explain ARVC pathogenesis do not explain all cases, and advances in genetic technology have allowed to elucidate genetic mechanisms, with desmosomal mutations attracting much attention. As reviewed here, various non-mutually exclusive pathogenetic mechanisms therefore appear to underlie ARVC.
Journal of Cytology & Histology · 2015 · 2 citations
Arrhythmogenic Right Ventricular Cardiomyopathy and Heart Transplantation: Two Cases
AbstractArrhythmogenic right ventricular cardiomyopathy (ARVC) is a myocardial disease characterized by fibrofatty replacement. The main clinical features are sudden death due to ventricular arrhythmias and congestive heart failure. Diagnosis of ARVC is still problematic and frequently made only by autopsy. Criteria for orthotropic heart transplant (HTx) have still not well been defined. We present two cases of arrhythmogenic right ventricular cardiomyopathy who underwent heart transplant. They demonstrate that heart transplant can be a real therapeutic option for these patients and offer to us the possibility to confirm the diagnosis and better understand pathological and histological features of the disease.
AACN Advanced Critical Care · 2022 · 1 citations · open access
Arrhythmogenic Right Ventricular Cardiomyopathy: Overview and Case Study
AbstractThis article provides a broad overview of arrhythmogenic right ventricular cardiomyopathy, including evaluation, diagnosis, and treatment options. Nursing considerations and clinical management are reviewed through the lens of a case study. Early diagnosis to prevent sudden cardiac death is essential for patients with arrhythmogenic right ventricular cardiomyopathy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
